Pfizer concludes USD 43 billion acquisition of Seagen
New York: Pfizer Inc. has announced the successful completion of its acquisition of Seagen Inc., a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. “Cancer remains […]